2022
Epidermal Growth Factor Receptor Inhibition Is Protective in Hyperoxia‐Induced Lung Injury
Harris ZM, Sun Y, Joerns J, Clark B, Hu B, Korde A, Sharma L, Shin HJ, Manning EP, Placek L, Unutmaz D, Stanley G, Chun H, Sauler M, Rajagopalan G, Zhang X, Kang MJ, Koff JL. Epidermal Growth Factor Receptor Inhibition Is Protective in Hyperoxia‐Induced Lung Injury. Oxidative Medicine And Cellular Longevity 2022, 2022: 9518592. PMID: 36193076, PMCID: PMC9526641, DOI: 10.1155/2022/9518592.Peer-Reviewed Original ResearchConceptsAcute lung injuryEpidermal growth factor receptorAlveolar epithelial cellsLung injurySevere hyperoxiaEGFR inhibitionEpithelial cellsHyperoxia-Induced Lung InjuryRole of EGFRMurine alveolar epithelial cellsGrowth factor receptor inhibitionWorse clinical outcomesEpidermal growth factor receptor inhibitionHuman alveolar epithelial cellsWild-type littermatesPoly (ADP-ribose) polymeraseTerminal dUTP nickGrowth factor receptorClinical outcomesImproved survivalReceptor inhibitionLung repairProtective roleComplex roleEGFR deletion
2015
Ménétrier’s Disease: Its Mimickers and Pathogenesis
Huh WJ, Coffey RJ, Washington MK. Ménétrier’s Disease: Its Mimickers and Pathogenesis. Journal Of Pathology And Translational Medicine 2015, 50: 10-16. PMID: 26689786, PMCID: PMC4734964, DOI: 10.4132/jptm.2015.09.15.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsEGFR-directed antibodies increase the risk of severe infection in cancer patients
Altan M, Burtness B. EGFR-directed antibodies increase the risk of severe infection in cancer patients. BMC Medicine 2015, 13: 37. PMID: 25857245, PMCID: PMC4336483, DOI: 10.1186/s12916-015-0276-9.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorSevere infectionsMonoclonal antibodiesRole of EGFRDose modification strategiesMonoclonal antibody treatmentClinical trial designRisk of infectionPractice of oncologyGrowth factor receptorConstitutional symptomsAntibody treatmentHypersensitivity reactionsCancer patientsRadiation therapyTrial designSolid tumorsInfection riskInfectionFactor receptorAntibodiesFurther studiesPatientsRiskRelated articles
1995
Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms.
Scher H, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks Z, Mendelsohn J, Cordon-Cardo C. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clinical Cancer Research 1995, 1: 545-50. PMID: 9816014.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorTGF-alpha expressionTGF-alphaGrowth factor alphaGrowth factor receptorFactor alphaPattern of expressionEpithelial cellsProstate cancer cell growthAutocrine/paracrine interactionsStaining patternRole of EGFRAndrogen-independent tumorsFactor receptorUntreated primary tumorsMalignant prostate epithelial cellsAndrogen-independent diseaseImmunohistochemical staining patternHomogeneous staining patternProstate cancer progressionMalignant epithelial cellsPrimary prostate tumorsCancer cell growthAndrogen-independent conditionGrowth factor pathways
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply